Weight Loss
Written by Dr. Lori Martin, M.D., Medical Director, THRIVE 4 Peak Performance. Dr. Martin is a physician specializing in performance medicine, longevity, and metabolic health.
Related reading: GLP-1 Weight Loss at THRIVE | GLP-1 Weight Loss: What to Expect | About THRIVE — Physician-Led Wellness
If you've been researching medical weight loss, you've almost certainly encountered two names: semaglutide and tirzepatide. Sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, these GLP-1 receptor agonists have reshaped what's possible in physician-supervised weight management. Both medications produce clinically meaningful weight loss — but they work differently, carry different efficacy profiles, and are not equally suited to every patient.
At THRIVE 4 Peak Performance in Alpharetta, our physicians evaluate each patient's metabolic health, goals, and medical history before recommending a GLP-1 protocol. This guide gives you an honest, clinical comparison of both medications so you can walk into that consultation with an informed perspective.
Both semaglutide and tirzepatide are injectable medications administered once weekly. Both act on GLP-1 receptors — glucagon-like peptide-1 receptors found in the gut, pancreas, and brain. When these receptors are activated, a cascade of metabolic effects follows: insulin secretion rises in response to meals, glucagon is suppressed (reducing liver glucose output), gastric emptying slows, and — critically — appetite-regulating centers in the hypothalamus signal reduced hunger and increased satiety.
The practical result is that patients eat less without white-knuckling willpower. Food noise — the near-constant mental preoccupation with food that drives overeating — decreases substantially in most patients. This is not a stimulant-based appetite suppressant or crash diet. It is a targeted intervention on the hormonal architecture of appetite regulation.
Key distinction: Semaglutide is a GLP-1 receptor agonist only. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism is the core reason tirzepatide consistently produces greater weight loss in clinical trials.
Semaglutide at the weight-loss dose (2.4 mg weekly, marketed as Wegovy) was studied in the landmark STEP trial series. The STEP 1 trial — the pivotal Phase 3 study — enrolled 1,961 adults with obesity and demonstrated an average weight loss of approximately 15% of body weight over 68 weeks among those who completed the treatment. That represented a meaningful departure from previously available medications.
Patients on semaglutide also showed improvements in cardiovascular risk markers, blood pressure, waist circumference, and blood glucose regulation. The SELECT cardiovascular outcomes trial subsequently confirmed a 20% reduction in major cardiovascular events in patients with overweight or obesity and established cardiovascular disease — a landmark finding that helped reframe GLP-1 therapy as more than cosmetic weight loss.
Tirzepatide's addition of GIP agonism on top of GLP-1 activation appears to produce synergistic metabolic effects. GIP receptors are present in adipose tissue, and their activation — combined with GLP-1's effects — leads to greater reductions in fat mass and body weight than GLP-1 alone can achieve. The SURMOUNT trial series established tirzepatide's efficacy profile.
SURMOUNT-1, the key Phase 3 trial, showed average weight reductions of 20.9% at the 15 mg dose over 72 weeks — with approximately one-third of participants achieving ≥25% body weight reduction. These are numbers that approach what has historically only been seen with bariatric surgery in selected populations. For many patients with significant excess weight who have failed other interventions, this represents a genuine clinical option.
Because both medications act on overlapping receptor systems, their side effect profiles are similar in character, though they may differ in intensity. The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are almost universally dose-dependent and most pronounced during dose escalation. They tend to improve significantly as patients adjust to each dose level.
At THRIVE, our physicians manage GLP-1 side effects through careful titration — starting patients at the lowest dose and advancing slowly based on tolerance. We also counsel patients on dietary modifications during the early phases of treatment (smaller portions, lower-fat meals, reduced alcohol) that materially reduce GI discomfort. Most patients who experience early nausea find it largely resolves within 4–6 weeks of reaching a stable dose.
Both medications also carry a class-wide warning regarding medullary thyroid carcinoma (based on animal studies) and pancreatitis risk, and are contraindicated in patients with a personal or family history of these conditions. Your physician will review your complete medical history before prescribing either agent.
The answer depends on a combination of clinical factors and personal goals. Here is how we generally think about it at THRIVE:
Semaglutide may be the better choice if: You have established cardiovascular disease and want the strongest outcomes data, you have had previous GI intolerance to GLP-1 medications, you are seeking moderate weight loss (10–18% body weight), or you prefer a medication with a longer real-world track record.
Tirzepatide may be the better choice if: You need maximum weight loss efficacy, your primary goal is significant fat mass reduction, you have not responded adequately to semaglutide in the past, or you have type 2 diabetes with insulin resistance (tirzepatide has particularly strong glycemic data).
It is also worth noting that individual response varies. Some patients achieve excellent results on semaglutide; others find tirzepatide's dual mechanism produces dramatically different outcomes for them personally. This is one reason physician oversight matters — having a clinician monitor your progress, adjust dose timing, and modify the protocol based on your actual response produces better outcomes than a fixed protocol alone.
Our physicians will evaluate your health history, metabolic profile, and goals to determine whether semaglutide or tirzepatide — or an alternative approach — is the right fit for you. Physician-supervised GLP-1 therapy in a clinical setting, not a med spa.
Book a Consultation Call (470) 359-6195GLP-1 medications are frequently available through online telehealth services with minimal clinical oversight. At THRIVE, we take a different approach. Every GLP-1 patient receives a physician evaluation before starting, regular check-ins to assess progress and tolerance, guidance on nutrition and exercise that compounds the medication's effects, and monitoring of metabolic markers over time. We also pair GLP-1 therapy with supportive services — including IV therapy for nutrient support and peptide protocols that help preserve lean mass during weight loss — that significantly improve the quality of your outcome.
The goal is not just a number on a scale. It is sustainable metabolic change, preserved muscle mass, and a body composition that reflects your performance goals.
Yes — transitioning between GLP-1 medications is possible and sometimes clinically appropriate. If you have plateaued on semaglutide or want to pursue greater weight loss, a physician can guide the transition, including appropriate washout periods and starting doses for tirzepatide. This should always be done under medical supervision.
Our GLP-1 weight loss program includes physician evaluation and access to medically appropriate GLP-1 therapies. Please schedule a consultation so our physicians can assess which medication protocol is appropriate for your individual case.
GLP-1 medications are not a short-term course the way an antibiotic is. The clinical data shows that patients who discontinue GLP-1 therapy typically regain a significant portion of lost weight over 12 months. Long-term — possibly lifelong — maintenance is a realistic expectation for many patients. Your physician will discuss this honestly in the context of your goals and overall health plan.
This is a meaningful clinical concern. Weight lost on GLP-1 therapy includes both fat mass and lean mass. The ratio of lean-to-fat mass lost depends significantly on protein intake and resistance exercise during treatment. At THRIVE, our protocols actively address this — we provide nutrition guidance focused on adequate protein, and we can support muscle preservation with complementary therapies including peptide therapy when appropriate.
THRIVE 4 Peak Performance is located at 3568 Old Milton Pkwy, Alpharetta, GA 30005. We serve Alpharetta, Milton, Roswell, Johns Creek, and surrounding North Atlanta communities. Call (470) 359-6195 to schedule a GLP-1 consultation.